Russian Biotech Sector is Good News for U.S. Companies

Posted by Laura Swartz

July 22, 2013 at 2:05 PM

An article published last week on FierceBiotech described Russia's current biotech focus and the opportunities this may hold for U.S. companies. Over the past year or so, Russia has been increasingly focused on biotechnology companies as a way to diversify its $1.9 trillion economy. In particular, Russia's OAO Rusnano (formerly the state-owned Russion Corporation of Nanotechnologies, which was transitioned into Rusnano in President Vladimir Putin's second term) has purchased stakes in R&D companies from Europe, Israel, and the U.S. Such investments often require the transfer of technologies to Russia or are accompanied by the establishment of Russian-based laboratories, scientists, and patent rights, as noted in an article from BloombergBusinessweek.

Read More

Topics: Newsworthy Events, AtheroNova, AtheroNova

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic